Rhythm Pharmaceuticals Inc (RYTM)

Rhythm Pharmaceuticals Inc (RYTM) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $6.3B; returns 1 day -1.8%, 1 week +3.6%, 1 year -18.2%.

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare genetic diseases of obesity. The company's entire product revenue is generated from its flagship drug, IMCIVREE (setmelanotide), a first-in-class melanocortin-4 receptor (MC4R) agonist.

Groups RYTM belongs to

• Biotechnology
• Biopharmaceutical
• Commercial Stage Biotech
• Rare Diseases
• Weight Management
• Precision Medicine
• Healthcare
• Endocrinology
• Metabolic Disorders
• Commercial Stage
• Pharmaceuticals
• Life Sciences

RYTM financial model: income statement, cash flow and balance sheet